Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Bachetti, T.
Right arrow Articles by Ferrari, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bachetti, T.
Right arrow Articles by Ferrari, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

The European Society of Cardiology

Anti-cytokine therapy in chronic heart failure: new approaches and unmet promises

Tiziana Bachettia, Laura Cominia, Evasio Pasinia and Roberto Ferrarib,*

a Cardiovascular Pathophysiology Research Center, S. Maugeri Foundation IRCCS, Gussago, Brescia, Italy
b Department of Cardiology, University of Ferrara, Corso Giovecca, 203, 44100 Ferrara, Italy

* Correspondence: Tel.: +39 532 202143; fax: +39 532 241885 (E-mail: fri{at}dns.unife.it).

Abstract

Until some decades ago chronic heart failure (CHF) has been considered a haemodynamic disorder with neurohormonal activation. Thus, the therapeutic strategies were oriented to correct cardiovascular disarrangement and counteract neurohormones. Although these therapeutic interventions improved CHF prognosis, mortality and morbidity CHF related remained high. In the recent years experimental and clinical researches increased our knowledge on CHF pathophysiology. Specifically, the involvement of inflammatory cytokines in the progression of CHF become more and more evident.

Therefore, correction of cytokine network may represent a new therapeutic strategy approach in the management of CHF. However, results obtained from the first clinical trials with engineered anti-cytokine molecules, such as Infliximab and Etanercept, are discouraging.

More knowledge on the complex interplay among inflammatory molecules in heart failure will allow its transfer to the design of more effective therapeutic candidates.

The present review addresses current information on this controversial issue.

Keywords Inflammatory molecules; Heart failure; Endothelium; Anti-cytokine molecules


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.